Saturday, December 7, 2013

Look at what One of the Slides at FDLI’s Annual Enforcement, Litigation and Compliance Conference Covers As a Priority--

Daniel McChesney, Director, Office of Surveillance and Compliance, CVM | Slides

CVM: 2013 Priorities and Activities
• Compounding and unapproved animal drugs
– Human drug compounding and animal drug
compounding
• Legislation
• Applicability of similar approaches
• CPG for animal drug compounding
– Are different approaches for animals intended for food and
those not intended for food
– Compounding from bulk drug
– Positive and negative lists

CVM: 2014 Priorities
• Eliminate FOIA backlog
• Address current lawsuits
• Process/staff to address FOIA in real-time
• Avoid future lawsuit’s due to response time
• Implements guidance 213 and VFD regulations
• Improve Section 105 data reporting and
transparency
Support drug approval process by addressing 
competing unapproved and/or compounded 
products 

found here

No comments: